Aristotle University Of Thessaloniki (AUTH)
Μελέτη της επιδράσεως του αντιαγγειογενετικού παράγοντα sorafenib στην ηπατική αναγέννηση: πειραματική μελέτη σε επίμυες
Abstract
dc:descriptionLiver has the unique ability to regenerate and thereby restore its original mass after tissue loss. This regenerative capacity of the liver is considered to be vital for the survival of patients submitted to extensive liver resection for the treatment of malignant liver tumors. Hepatocellular carcinoma is the most common primary malignant liver tumor, the fifth most common type of cancer worldwide, and the third leading cause of cancer mortality. Liver transplantation and liver resection are considered as potentially curative treatments, and are the standard of care for patients with early-stage hepatocellular carcinoma. In patients with advanced carcinoma and Child–Pugh A liver disease, treatment with Sorafenib, an orally active multikinase inhibitor with antiangiogenic and antiproliferative properties, resulted in a survival extension. The molecular pathways inhibited by Sorafenib augment angiogenesis and cell division, both of which are integral components of liver regeneration. The aim of the present study was to investigate how pretreatment with Sorafenib influences liver regeneration and angiogenesis in healthy rats, after partial hepatectomy 2/3. Animals were allocated to two groups and further divided into three subgroups. Animals received either vehicle for Sorafenib (placebo) or 30mg/kg/day of Sorafenib by gavage for 14 days preoperatively, underwent partial hepatectomy and were sacrificed at 48, 96 or 168 hours postoperatively, respectively. The results of the statistical analysis that was performed, conclude that Sorafenib significantly reduced the restoration of liver remnant and considerably reduced proliferation of hepatocytes at 48 and 96 hours after partial hepatectomy 2/3. Light microscopy of tissue specimens revealed that the characteristic changes of liver regeneration were more prominent in the animals receiving only the vehicle. Hepatocellular DNA synthesis was estimated using immunohistochemical staining for the Ki-67 antigen. Sorafenib neither reduced DNA synthesis, nor neoangiogenesis at any time point, as it was assessed by CD34 immunostaining. As biochemical markers are concerned, no significant changes were observed, apart from a transient raise of SGOT and ALP values at 48 hours after hepatectomy. Biochemical markers, useful in indicating liver dysfunction especially regarding drug hepatotoxicity, cannot be used to estimate liver regeneration or neoangiogenesis. This study’s finding, that Sorafenib reduces the regeneration and angiogenesis incompletely and transiently, cannot be translated into the clinical setting. Potential confirmation of this study’s findings by future randomized experimental and clinical studies, would imply that Sorafenib could be used as neoadjuvant treatment for patients with hepatocellular carcinoma prior to liver resection, extending survival rate and improving their quality of life. Nevertheless, further experimental and clinical studies with randomized trials have to take place, aiming to verify its safety and determine its efficacy. Treatment could be better with less adverse effects, compared to cell-static drugs, receiving higher compliance due to being bearable for the majority of the patients being administrated. Last but not least, taking into consideration that anti-angiogeneic factors can reduce or even eliminate cancer cells, leading to the reduction of cancer recurrence possibility, a new era of treatment for hepatocellular cancer begins by the introduction of more effective approaches, such as combinations of treatments.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kiroplastis, Konstantinos
- Κηροπλάστης, Κωνσταντίνος
Subjects
dc:subject × 15- Sorafenib
- Μερική ηπατεκτομή
- Αγγειογένεση
- Ηπατική αναγέννηση
- Ηπατοκυτταρικό καρκίνωμα - ΗΚΚ
- Αντιαγγειογενετικός παράγοντας
- Partial hepatectomy - PH
- Angiogenesis and neoangiogenesis
- Liver regeneration
- Hepatocellular carcinoma - HCC
- Angiogenesis inhibitor
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/36270